Treats gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. ANDA 40632, held by Hikma Pharmaceuticals. Methotrexate Sodium.
As of Nov 21, 2026, ANDA 40632 (Methotrexate Sodium Preservative Free), held by Hikma Pharmaceuticals, was first approved by FDA on Aug 12, 2005, with 4 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Neoplastic Diseases Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is also indicated in the treatment of meningeal leukemia. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 12, 2005 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Methotrexate Sodium Preservative FreeEQ 1GM BASE/VIAL · injectable;injection | Methotrexate Sodium | Rx |
| Aug 18, 2025 | Supplement 11Labeling · Standard review | Approved | None posted |
| Aug 18, 2025 | Supplement 16Labeling · Standard review | Approved | None posted |
| Feb 5, 2013 | Supplement 6Labeling | Approved | None posted |
| Mar 8, 2011 | Supplement 4Labeling | Approved | None posted |
| Aug 12, 2005 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters